HA
CLDX icon

HC Advisors’s Celldex Therapeutics CLDX Stock Holding History

HC Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,345
Closed -$238K – 83
2022
Q4 		$238K Sell
5,345
-6,790
-56% -$242K 0.16% 67
2022
Q3 		$341K Buy
12,135
+4,510
+59% +$138K 0.23% 57
2022
Q2 		$206K Sell
7,625
-50
-0.7% -$1.45K 0.15% 73
2022
Q1 		$261K Sell
7,675
-508
-6% -$16.2K 0.17% 70
2021
Q4 		$316K Buy
8,183
+2,694
+49% +$117K 0.19% 59
2021
Q3 		$296K Sell
5,489
-927
-14% -$43.5K 0.19% 60
2021
Q2 		$215K Buy
+6,416
New +$176K 0.13% 74
2021
Q1 		– Sell
-14,791
Closed -$259K – 92
2020
Q4 		$259K Buy
14,791
+2,210
+18% +$39.8K 0.18% 70
2020
Q3 		$187K Buy
+12,581
New +$147K 0.15% 70

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

HC Advisors's CLDX Position: Q1 2023 in Review

HC Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 5,345 shares — an estimated $238K sold.

HC Advisors first reported a position in CLDX in Q3 2020 and held it in 9 quarters. The position peaked at $341K in Q3 2022. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • HC Advisors reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • HC Advisors sold 5,345 Celldex Therapeutics shares in Q1 2023, an estimated $238K.
  • HC Advisors first reported a position in Celldex Therapeutics in Q3 2020 and held it in 9 quarters.
  • HC Advisors's Celldex Therapeutics position peaked at $341K in Q3 2022.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on HC Advisors's 13F filing for Q1 2023, filed 8 May 2023.